📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-04 14:50
709 analysed today
709
Today
133,598
All-time analysed
40,124
Positive
6,284
Negative
79,370
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
21 announcements match the current filters (relevance ≥ 5).
TTK Healthcare Completes Sale of EVA & Good Home Brands for ₹256 Cr Cash
TTK Healthcare has completed the sale of its 'EVA' and 'Good Home' brands to Wipro Enterprises Private Limited, receiving a cash consideration of ₹256 crore plus applicable GST. The transaction closes the definitive agreement executed on July 23, 2026. The ₹256 crore cash inflow represents approximately 29.9% of TTM revenue (₹857 crore) and 16.4% of the company's market capitalization (₹1,557 crore). This significantly boosts the company's existing cash reserves, which previously stood high following its human pharma divestment.
Confidence: HIGH
What changedTTK Healthcare successfully closed the transaction and received ₹256 crore in cash from Wipro Enterprises for the transfer of 'EVA' and 'Good Home' brands.
Why it mattersThe ₹256 crore cash infusion significantly bolsters the balance sheet and liquidity, though it will reduce consumer division revenue going forward as these brands are handed over.
Cash consideration received: Rs.256 croresDeal value vs Market cap: ~16.4%Deal value vs TTM revenue: ~29.9%Agreement date: July 23, 2026Closing date: September 04, 2026
📅 Short termPositive for stock sentiment due to the substantial cash realization and closure of the deal with Wipro Enterprises.
📈 Long termThe company's core operations narrow down to Gripe Water, contraceptives, medical devices, and foods, with a very large cash kitty available for redeployment or shareholder distribution.
⚠ Risk flags
- Loss of revenue and operating profit contribution from the divested EVA and Good Home product lines
- Reinvestment risk regarding the large cash reserves
Key Highlights
Received ₹256 crore plus applicable GST in cash consideration on September 04, 2026
Divestment of 'EVA' and 'Good Home' brands to Wipro Enterprises stands completed
Definitive agreements were previously signed on July 23, 2026
Deal consideration represents ~29.9% of TTM revenue of ₹857 crore
👀 What to Watch
Watch for management commentary in the upcoming quarterly results regarding capital allocation plans, special dividend distribution, or potential redeployment of the cash surplus.
63% PAT Growth in Q1; TTK Healthcare to Sell EVA & Good Home Brands for Rs 256 Cr
TTK Healthcare reported a strong Q1 FY26 with revenue growing 13.7% YoY to Rs 257.56 Cr and PAT rising 63.7% to Rs 21.28 Cr. A major highlight is the definitive agreement to sell the 'EVA' and 'Good Home' brands to Wipro Enterprises for Rs 256 Cr, representing approximately 30% of TTM revenue. The company also successfully recovered Rs 5.10 Cr from previously written-off USAID orders in the Protective Devices segment. Profitability was significantly bolstered by a turnaround in the Protective Devices division, which moved from a loss to a Rs 6.13 Cr profit.
Confidence: HIGH
What changedTTK Healthcare has formalized a major brand divestment and demonstrated a sharp operational recovery in its Protective Devices (contraceptives) segment.
Why it mattersThe Rs 256 Cr cash inflow (approx. 16.6% of market cap) significantly strengthens an already low-debt balance sheet and allows the company to focus on its remaining core segments or new acquisitions.
Q1 FY26 Revenue: Rs 257.56 CrQ1 FY26 PAT: Rs 21.28 CrBrand Sale Consideration: Rs 256 CrSale Value vs TTM Revenue: ~30%USAID Order Recovery: Rs 5.10 Cr
📅 Short termThe stock is likely to react positively to the strong earnings growth and the substantial cash realization from the brand sale.
📈 Long termThe company is transitioning its portfolio; the primary long-term value driver will be the effective deployment of its massive cash pile (divestment proceeds plus existing surplus).
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Loss of revenue and margins from the divested high-profile brands (EVA/Good Home)
- Execution risk in reinvesting the large cash surplus effectively
Key Highlights
Net Profit for Q1 FY26 rose to Rs 21.28 Cr from Rs 13.00 Cr in the same quarter last year.
Agreed to divest EVA and Good Home brands to Wipro Enterprises for Rs 256 Cr, expected to close by Sept 30, 2026.
Protective Devices segment profit turned around to Rs 6.13 Cr from a loss of Rs 5.44 Cr YoY.
Invoiced Rs 5.10 Cr worth of inventory to USAID that was previously written off in FY25.
Earnings Per Share (EPS) increased to Rs 15.06 for the quarter compared to Rs 9.20 in Q1 FY25.
👀 What to Watch
Monitor the completion of the Rs 256 Cr brand sale by September 30, 2026, and watch for management commentary on the deployment of the resulting cash surplus.
63.7% PAT Growth in Q1 FY26; TTK Healthcare to Sell Brands for ₹256 Cr
TTK Healthcare reported a strong Q1 FY2026 with revenue growing 13.7% YoY to ₹257.56 cr and PAT increasing 63.7% to ₹21.28 cr. A major highlight is the definitive agreement to sell the 'EVA' and 'Good Home' brands to Wipro Enterprises for ₹256 cr, which represents approximately 30% of the company's TTM revenue. The company also recovered ₹5.10 cr from previously written-off USAID orders in the Protective Devices segment, boosting margins. With unallocated assets now at ₹976.23 cr, the company is exceptionally cash-rich relative to its ₹1,538 cr market cap.
Confidence: HIGH
What changedTTK Healthcare has transitioned from a diversified manufacturer to a highly liquid entity by agreeing to divest two key consumer brands for ₹256 cr while delivering a significant earnings beat.
Why it mattersThe brand sale provides a massive liquidity boost (approx. 16.6% of market cap) to a company that already had a large cash surplus. This creates significant optionality for future M&A or capital return, though it will lead to a loss of revenue from the divested brands in future quarters.
Q1 Revenue: ₹257.56 crQ1 PAT: ₹21.28 crBrand Sale Value: ₹256 crSale Value vs TTM Revenue: 29.9%Unallocated Assets: ₹976.23 cr
📅 Short termThe stock is likely to react positively to the strong earnings growth and the high valuation realized for the EVA and Good Home brands.
📈 Long termThe long-term trajectory depends entirely on how the company deploys its massive cash reserves (exceeding ₹1,000 cr post-sale) following the divestment of its human pharma and consumer brand assets.
⚠ Risk flags
- Loss of revenue and operating leverage from divested brands
- High reliance on outsourced manufacturing
- Execution risk in deploying large cash reserves
Key Highlights
Revenue from operations increased 13.7% YoY to ₹257.56 cr for the quarter ended June 30, 2026.
Net Profit surged 63.7% YoY to ₹21.28 cr compared to ₹13.00 cr in the same quarter last year.
Definitive agreement signed with Wipro Enterprises to sell EVA and Good Home brands for ₹256 cr.
Protective Devices segment revenue grew to ₹60.98 cr, supported by ₹5.10 cr in recovered USAID orders.
Unallocated assets (primarily cash/investments) reached ₹976.23 cr as of June 30, 2026.
👀 What to Watch
Monitor the completion of the brand sale transaction expected by September 30, 2026, and subsequent management commentary on the deployment of the ₹1,000 cr+ cash pile. Investors should also track if the margin improvement in the Protective Devices segment is sustainable post-USAID order recovery.
₹256 Cr Brand Divestment and ₹900 Cr Cash Surplus Highlighted at 68th AGM
TTK Healthcare reported FY26 revenue of ₹857.28 cr, a 7% growth, though pre-tax profit fell to ₹82.56 cr due to the loss of USAID tender business in the Protective Devices segment. The company announced the divestment of its 'EVA' and 'Good Home' brands to Wipro Enterprises for ₹256 cr, which contributed ₹148 cr to FY26 revenue. Most notably, the company now holds a massive cash balance of ~₹900 cr, representing approximately 61% of its current market capitalization. A dividend of ₹10 per share (100%) was recommended.
Confidence: HIGH
What changedThe company is divesting two major consumer brands (EVA and Good Home) and has significantly increased its cash reserves to ₹900 cr.
Why it mattersThe brand sale represents ~30% of TTM revenue and provides a massive liquidity cushion, though it creates a temporary revenue gap that needs to be filled by other segments like Ortho or new acquisitions.
Brand Divestment Value: ₹256 crDivestment vs TTM Revenue: ~30%Cash Balance: ₹900 crCash vs Market Cap: ~61%FY26 Revenue Growth: 7%Dividend per Share: ₹10.00
📅 Short termThe stock may see positive sentiment due to the high valuation achieved for the brand divestment and the substantial cash-per-share floor.
📈 Long termThe company is undergoing a structural shift, moving away from certain consumer segments toward medical devices and animal welfare; long-term value depends on the efficient allocation of the ₹900 cr cash pile.
⚠ Risk flags
- Loss of high-margin institutional/tender business (USAID)
- Revenue concentration risk following brand divestments
- Execution risk in clinical trials for new medical devices
Key Highlights
Divestment of EVA and Good Home brands to Wipro for ₹256 cr plus GST
Cash and bank balances reached ~₹900 cr as of March 31, 2026
Ortho Division reported strong revenue growth of 27% in FY26
Divested brands (EVA and Good Home) had a combined turnover of ₹148 cr in FY26
Proposed pivotal clinical study for TC2 Titanium Heart Valve involving 400 patients
👀 What to Watch
Monitor the deployment strategy for the ₹900 cr cash surplus, as the company continues to divest non-core brands. Investors should track the margin impact of losing the ₹148 cr consumer brand revenue versus the interest income or acquisition potential from the new cash inflow.
₹256 Cr Brand Sale: TTK Healthcare to Divest EVA and Good Home Brands to Wipro
TTK Healthcare has signed definitive agreements to sell its 'EVA' and 'Good Home' brands to Wipro Enterprises for a total consideration of ₹256 crores. These brands contributed approximately ₹148 crores to the company's revenue in FY2025-26, accounting for 17% of total turnover. The transaction is expected to conclude by September 30, 2026, subject to customary closing conditions. This move further increases the company's significant cash reserves, which were already bolstered by a previous human pharma divestment.
Confidence: HIGH
What changedTTK Healthcare is exiting the personal care (EVA) and home care (Good Home) brand segments through a brand sale to Wipro Enterprises.
Why it mattersThe deal unlocks significant value (valued at ~1.7x brand revenue) and adds to a cash-heavy balance sheet, though it will result in a 17% immediate reduction in total revenue.
Sale Consideration: ₹256 crBrand Revenue (FY26): ₹148 crRevenue Contribution %: 17%Consideration vs Market Cap: ~18%Expected Completion Date: September 30, 2026
📅 Short termThe stock is likely to react positively to the cash infusion and the valuation achieved for the brands.
📈 Long termStructural significance depends on how the company redeploys its cash pile (over ₹1,000 cr) into higher-margin businesses or acquisitions, given the 17% revenue loss from this divestment.
⚠ Risk flags
- Revenue concentration risk increases as 17% of the top line is removed
- Reinvestment risk regarding the large cash balance
Key Highlights
Total sale consideration of ₹256 crores plus applicable GST
Divested brands contributed ₹148 crores (17%) to the FY2025-26 revenue
Transaction expected to be completed by September 30, 2026
Buyer is Wipro Enterprises Private Limited, a non-promoter third party
Sale consideration represents approximately 18% of the company's current market capitalization
👀 What to Watch
Investors should monitor the company's strategy for deploying its massive cash surplus, which now likely exceeds ₹1,000 crores, and watch for any margin improvements as the company streamlines its portfolio.
Rs 256 Cr Brand Sale: TTK Healthcare to Divest EVA and Good Home Brands to Wipro
TTK Healthcare has entered into a definitive agreement to sell its 'EVA' and 'Good Home' brands to Wipro Enterprises Private Limited for a total consideration of Rs 256 crore. These brands contributed approximately Rs 148 crore to the company's FY26 revenue, representing 17% of its total turnover. The transaction is expected to close by September 30, 2026, and will significantly increase the company's already substantial cash reserves. This move follows the company's previous large-scale divestment of its human pharma division.
Confidence: HIGH
What changedTTK Healthcare is exiting the personal care (EVA) and home care (Good Home) segments by selling these brands to Wipro Enterprises.
Why it mattersThe sale unlocks significant value for brands that were contributing 17% of revenue but likely required high marketing spend. The company is now extremely cash-rich relative to its market cap, shifting the investment thesis toward capital allocation and potential new acquisitions.
Sale Consideration: Rs 256 crBrand Revenue (FY26): Rs 148 crRevenue Contribution %: 17%Deal Value vs Market Cap: ~18%Expected Completion Date: September 30, 2026
📅 Short termThe stock is likely to react positively to the cash infusion and the valuation multiple achieved for the brands (approx 1.7x brand revenue).
📈 Long termThe company is structurally transforming into a cash-heavy entity. Long-term performance depends on whether management can reinvest the ~Rs 1,000+ cr cash pile into higher-margin businesses than the divested segments.
⚠ Risk flags
- Loss of 17% of total revenue
- Reinvestment risk of large cash balances
- Increased dependence on remaining niche segments like contraceptives and gripe water
Key Highlights
Total sale consideration of Rs 256 crore plus applicable GST
Divested brands contributed Rs 148 crore (17%) to FY25-26 turnover
Transaction expected to be completed by September 30, 2026
Sale value represents approximately 18% of the company's current market capitalization of Rs 1,417 crore
Buyer is Wipro Enterprises Private Limited, a non-related party
👀 What to Watch
Investors should monitor the company's strategy for deploying its massive cash surplus, which now exceeds Rs 1,000 crore including previous divestment proceeds, as this will be the primary driver of future value.
TTK Healthcare Sets July 17, 2026, as Record Date for Dividend and 68th AGM
TTK Healthcare Limited has announced July 17, 2026, as the record date for determining shareholder eligibility for its upcoming dividend and voting rights. The company's 68th Annual General Meeting (AGM) is scheduled to take place on July 24, 2026, at 12:00 PM via video conferencing. Shareholders must hold the stock by the record date to be eligible for the dividend payout and to participate in the voting process for corporate resolutions.
Key Highlights
Record date for dividend and voting rights fixed for July 17, 2026.
68th Annual General Meeting (AGM) scheduled for July 24, 2026, at 12:00 PM.
AGM to be conducted via Video Conferencing (VC) or Other Audio-Visual Means (OAVM).
Shareholders listed as of the cut-off date (July 17) will be eligible for the dividend distribution.
👀 What to Watch
Investors interested in the dividend should ensure they hold the shares before the ex-dividend date, which typically precedes the July 17 record date. Existing shareholders should also prepare to participate in the virtual AGM to stay informed on company governance.
TTK Healthcare FY26 Revenue Up 7% to ₹857 Cr; Recommends ₹10 Dividend
TTK Healthcare reported a steady 7% growth in annual revenue from operations, reaching ₹857.28 crore for FY26. Net profit for the year declined to ₹65.68 crore from ₹81.66 crore in FY25, primarily due to a high base effect from a ₹19.77 crore land sale profit in the previous year. The Board has recommended a dividend of ₹10 per share (100% of face value). Additionally, the company has reappointed Mr. T T Raghunathan as Executive Chairman for a further five-year term starting November 2026.
Key Highlights
Revenue from operations grew 6.96% YoY to ₹857.28 crore in FY26 compared to ₹801.49 crore in FY25.
Net Profit for the year stood at ₹65.68 crore with an EPS of ₹46.48, down from ₹81.66 crore in the previous year.
Recommended a final dividend of ₹10 per equity share (100%) for the financial year ended March 31, 2026.
Recognized an exceptional income of ₹350.41 lakhs in Q4 FY26 pertaining to GST refunds from earlier periods.
Total Assets increased to ₹1,328.74 crore as of March 31, 2026, up from ₹1,281.19 crore in the previous year.
👀 What to Watch
The profit decline is primarily due to non-recurring gains in the previous year rather than operational deterioration; investors should focus on the steady revenue growth and consistent dividend payout. Monitor the impact of the new Wage Structure implementation planned for FY 2026-27.
TTK Healthcare FY26 Net Profit Drops 19.5% to ₹65.68 Cr; ₹10 Dividend Declared
TTK Healthcare reported a 7% year-on-year growth in revenue from operations to ₹857.28 crore for FY26. However, net profit for the year declined significantly to ₹65.68 crore from ₹81.66 crore in FY25, primarily due to higher expenses and exceptional items. The company recognized a net exceptional charge of ₹7.58 crore related to the incremental impact of new Labour Codes on employee benefits. Despite the profit dip, the board has recommended a dividend of ₹10 per equity share (100% of face value).
Key Highlights
Revenue from operations increased 7% YoY to ₹857.28 crore in FY26 compared to ₹801.49 crore in FY25.
Net profit for FY26 fell to ₹65.68 crore, down from ₹81.66 crore in the previous fiscal year.
Earnings Per Share (EPS) declined to ₹46.48 from ₹57.79 in the prior year.
Recommended a dividend of ₹10 per equity share (100%) for the financial year ended March 31, 2026.
Exceptional items included a ₹7.58 crore charge for Labour Code compliance and a ₹3.50 crore GST refund.
👀 What to Watch
Investors should be cautious as the decline in profitability and EPS suggests margin pressure despite revenue growth. Monitor the impact of the new wage structure and labour codes on future operating margins.
TTK Healthcare FY26 Revenue Rises 7% to ₹857 Cr; Declares ₹10 Dividend per Share
TTK Healthcare reported a steady 7% YoY growth in annual revenue to ₹857.28 crore for FY26. However, Profit After Tax (PAT) declined by 19.5% to ₹65.68 crore from ₹81.66 crore in FY25, primarily due to a net exceptional charge of ₹4.07 crore and a high base effect from the previous year's exceptional gains. The company has recommended a dividend of ₹10 per share (100%) and approved the reappointment of Mr. T T Raghunathan as Executive Chairman for another five-year term.
Key Highlights
Annual Revenue from Operations increased to ₹857.28 crore in FY26 compared to ₹801.49 crore in FY25.
Net Profit for FY26 stood at ₹65.68 crore, down from ₹81.66 crore in the previous year.
Recommended a dividend of ₹10 per equity share of ₹10 each for the financial year ended March 31, 2026.
Exceptional items for FY26 included a ₹7.58 crore charge for Labour Code adjustments, partially offset by a ₹3.50 crore GST refund.
Executive Chairman T T Raghunathan reappointed for a 5-year term effective November 1, 2026.
👀 What to Watch
Investors should focus on the steady top-line growth while monitoring the impact of rising operational expenses on margins. The consistent dividend payout remains a positive for long-term shareholders.
TTK Healthcare Q4 Net Profit Rises to ₹21.76 Cr; ₹10 Dividend Declared
TTK Healthcare reported a strong performance for Q4 FY26, with net profit reaching ₹2,176.21 lakhs, a significant recovery from ₹1,053.26 lakhs in the previous quarter. For the full year FY26, total income grew to ₹92,943.11 lakhs compared to ₹87,274.83 lakhs in FY25. The Board has recommended a 100% dividend of ₹10 per share, reflecting healthy cash flows. Additionally, the company ensured leadership stability by reappointing Mr. T T Raghunathan as Executive Chairman for a five-year term starting November 2026.
Key Highlights
Net profit for Q4 FY26 stood at ₹2,176.21 lakhs, up from ₹1,053.26 lakhs in Q3 FY26.
Recommended a final dividend of ₹10 per equity share (100%) for the financial year 2025-26.
Annual revenue from operations increased to ₹85,728.11 lakhs in FY26 from ₹80,149.34 lakhs in FY25.
Reappointed Mr. T T Raghunathan as Executive Chairman for a further term of 5 years effective Nov 1, 2026.
Cash and cash equivalents improved to ₹2,144.14 lakhs as of March 31, 2026, compared to ₹900.64 lakhs in the previous year.
👀 What to Watch
Investors should consider the strong quarterly earnings and consistent dividend payout as signs of operational stability. The stock remains attractive for those seeking steady returns and management continuity.
TTK Healthcare FY26 Net Profit at ₹65.68 Cr; Recommends ₹10 Dividend per Share
TTK Healthcare reported a steady performance for FY26 with total income reaching ₹929.43 crore, up from ₹872.75 crore in FY25. Net profit for the year stood at ₹65.68 crore, a decline compared to ₹81.66 crore in the previous year, which was inflated by a significant one-time gain from a land sale. The company has maintained its dividend payout at ₹10 per share (100% of face value). Leadership remains stable with the re-appointment of Mr. T T Raghunathan as Executive Chairman for another five-year term.
Key Highlights
Revenue from operations grew 7% year-on-year to ₹857.28 crore in FY26.
Net Profit for the full year stood at ₹65.68 crore with an EPS of ₹46.48.
Board recommended a dividend of ₹10 per equity share for the financial year ended March 31, 2026.
Exceptional items for the year included a ₹3.50 crore GST refund and a ₹7.58 crore charge related to new Labour Code provisions.
Mr. T T Raghunathan re-appointed as Executive Chairman for a 5-year term effective November 1, 2026.
👀 What to Watch
Investors should focus on the core operational growth of 7% in revenue, as the bottom-line decline is primarily due to the absence of last year's large exceptional land sale gain. The consistent dividend and leadership continuity provide stability for long-term holders.
TTK Healthcare Recommends Rs 10 Dividend; FY26 Net Profit Jumps 24% to Rs 81.66 Crore
TTK Healthcare Limited reported a strong financial performance for the fiscal year ended March 31, 2026, with net profit rising 24.3% to Rs 81.66 crore from Rs 65.68 crore in the previous year. Total income grew to Rs 929.64 crore, supported by steady operations despite exceptional charges related to labor code adjustments. The Board has recommended a final dividend of Rs 10 per share (100% of face value), maintaining its payout policy. Additionally, the company has secured leadership continuity by reappointing Mr. T T Raghunathan as Executive Chairman for another five-year term.
Key Highlights
Recommended a final dividend of Rs 10 per equity share (100%) for the financial year 2025-26.
Annual Net Profit (PAT) increased by 24.3% YoY to Rs 8,165.69 lakhs from Rs 6,568.05 lakhs.
Total Income for FY26 rose to Rs 92,964.11 lakhs compared to Rs 85,728.11 lakhs in the previous fiscal.
Earnings Per Share (EPS) saw significant growth, rising to Rs 57.79 from Rs 46.48.
Reappointed Mr. T T Raghunathan as Executive Chairman for a further term of 5 years effective November 2026.
👀 What to Watch
Investors should take note of the robust 24% growth in net profit and the healthy dividend yield. The company's improved EPS and leadership stability make it a positive prospect for long-term portfolios.
TTK Healthcare FY26 Revenue Up 7% to ₹857 Cr; Net Profit at ₹65.68 Cr; ₹10 Dividend Declared
TTK Healthcare reported a steady 7% growth in annual revenue from operations, reaching ₹857.28 crore for the fiscal year ended March 31, 2026. Net profit for the year declined to ₹65.68 crore from ₹81.66 crore in the previous year, primarily due to a high base in FY25 which included significant one-time gains from land sales. The company maintained its dividend payout, recommending ₹10 per share (100% of face value), and confirmed the re-appointment of Mr. T T Raghunathan as Executive Chairman for another five-year term.
Key Highlights
Revenue from operations grew to ₹85,728.11 lakhs in FY26 compared to ₹80,149.34 lakhs in FY25.
Net Profit after tax stood at ₹6,568.05 lakhs, a decrease from ₹8,165.69 lakhs in the previous fiscal year.
Recommended a dividend of ₹10 per equity share (100%) for the financial year ended March 31, 2026.
FY26 results include a net exceptional charge of ₹757.87 lakhs related to the implementation of new Labour Codes.
Mr. T T Raghunathan re-appointed as Executive Chairman for a 5-year term effective November 1, 2026.
👀 What to Watch
Investors should focus on the consistent top-line growth while accounting for the fact that the previous year's profit was inflated by one-time asset sales. The steady dividend and management continuity are positive signs for long-term stability.
TTK Healthcare Q3 Net Profit Drops 37% to ₹10.53 Cr; Impacted by ₹7.58 Cr Exceptional Item
TTK Healthcare reported a 37% year-on-year decline in net profit for Q3 FY26, falling to ₹10.53 crore from ₹16.73 crore. While revenue remained relatively flat at ₹209.30 crore, the bottom line was severely impacted by a one-time exceptional charge of ₹7.58 crore related to the implementation of new Labour Codes. Segment-wise, the Consumer Products and Medical Devices divisions saw margin pressure, while the Protective Devices division continued to report losses. On a positive note, the Foods and Animal Welfare segments showed improved profitability during the quarter.
Key Highlights
Revenue from operations grew marginally by 2.2% YoY to ₹209.30 crore compared to ₹204.74 crore.
Net profit declined 37% YoY to ₹10.53 crore, primarily due to a ₹7.58 crore exceptional charge for labour code adjustments.
Consumer Products segment profit fell sharply to ₹2.25 crore from ₹6.45 crore in the previous year's quarter.
Protective Devices segment recorded a loss of ₹1.10 crore, widening from a loss of ₹0.31 crore YoY.
The company reconstituted its board committees following the retirement of Independent Director Mr. N Ramesh Rajan.
👀 What to Watch
Investors should monitor the recovery in the Consumer Products segment and the narrowing of losses in the Protective Devices division. While the profit dip is largely due to a non-recurring regulatory charge, the underlying operational weakness in core segments warrants a cautious approach.
TTK Healthcare Q3 Net Profit Drops 37% to ₹10.53 Cr; Impacted by ₹7.58 Cr Exceptional Item
TTK Healthcare reported a 37% year-on-year decline in net profit for Q3 FY26, falling to ₹10.53 crore from ₹16.73 crore. The bottom line was significantly impacted by a one-time exceptional charge of ₹7.58 crore related to the implementation of new Labour Codes affecting gratuity and leave provisions. While revenue from operations remained relatively flat at ₹209.30 crore, the Protective Devices segment continued to struggle, reporting a loss of ₹1.10 crore. Conversely, the Animal Welfare and Medical Devices segments showed healthy revenue growth during the quarter.
Key Highlights
Net Profit for Q3 FY26 fell 37% YoY to ₹1,053.26 lakhs compared to ₹1,673.24 lakhs in the previous year.
Revenue from operations grew marginally by 2.2% YoY to ₹20,929.89 lakhs.
Recognized a net exceptional charge of ₹757.87 lakhs due to the incremental impact of new Labour Codes on employee benefits.
Protective Devices segment reported a loss of ₹110.23 lakhs, continuing a trend of underperformance.
Animal Welfare and Medical Devices segments saw revenue growth of 15.5% and 19.1% YoY respectively.
👀 What to Watch
Investors should monitor the recovery in the Protective Devices segment and the stabilization of margins following the one-time labour code adjustments. The stock may face short-term pressure due to the sharp decline in quarterly profitability.
TTK Healthcare Q3 Net Profit Falls 37% to ₹10.53 Cr Due to ₹7.58 Cr Exceptional Labour Code Charge
TTK Healthcare reported a marginal 2.2% YoY growth in revenue from operations to ₹209.30 crore for Q3 FY26. However, Net Profit declined significantly by 37% YoY to ₹10.53 crore, primarily impacted by a one-time exceptional charge of ₹7.58 crore related to the implementation of new Labour Codes. While the Foods and Animal Welfare segments showed improved profitability, the core Consumer Products and Medical Devices divisions faced margin pressure, and the Protective Devices segment continued to report losses.
Key Highlights
Revenue from operations grew slightly to ₹209.30 crore in Q3 FY26 from ₹204.74 crore in Q3 FY25.
Net Profit dropped 37% YoY to ₹10.53 crore, down from ₹16.73 crore in the same quarter last year.
Recognized a net exceptional charge of ₹757.87 lakhs for incremental Gratuity and Long-term Compensated Absences following new Labour Code notifications.
Consumer Products segment profit slumped to ₹2.25 crore from ₹6.45 crore YoY, indicating significant margin pressure.
Foods segment performed strongly with profit rising to ₹3.40 crore compared to ₹1.43 crore in the previous year's quarter.
👀 What to Watch
The profit decline is largely attributed to a non-recurring regulatory accounting charge; however, the sharp drop in Consumer Products margins is a fundamental concern. Investors should monitor if the growth in the Foods segment can offset the volatility in the Protective and Consumer product divisions.
TTK Healthcare Appoints Former TTK Prestige CFO V Sundaresan as Independent Director
TTK Healthcare has appointed Mr. V Sundaresan as an Additional Independent Director for a five-year term effective December 22, 2025. Mr. Sundaresan is a veteran professional with nearly 40 years of experience, including a 30-year tenure within the TTK Group where he served as the CFO of TTK Prestige Ltd. The appointment is subject to shareholder approval via a postal ballot process, with voting concluding on January 24, 2026. His deep expertise in corporate finance, audit, and internal controls is expected to enhance the company's governance framework.
Key Highlights
Appointment of Mr. V Sundaresan as Additional Independent Director for a 5-year term starting December 22, 2025
Appointee previously served as CFO of TTK Prestige Ltd and has nearly 40 years of leadership experience in finance and audit
Shareholder approval to be sought through Postal Ballot with remote e-voting from December 26, 2025, to January 24, 2026
Final results of the postal ballot and director appointment confirmation expected by January 28, 2026
👀 What to Watch
Investors should view this as a positive governance move, bringing in a seasoned financial expert familiar with the group's operations. No immediate portfolio changes are required.
TTK Healthcare Appoints Former TTK Prestige CFO V Sundaresan as Independent Director
TTK Healthcare has appointed Mr. V Sundaresan as an Additional Independent Director for a five-year term effective December 22, 2025. Mr. Sundaresan brings nearly 40 years of experience in finance and audit, having previously served as the CFO of TTK Prestige for nearly three decades. The appointment is subject to shareholder approval via a postal ballot process ending January 24, 2026. This move strengthens the board's financial oversight and governance, leveraging his deep familiarity with the TTK Group's operations.
Key Highlights
Appointment of Mr. V Sundaresan as Additional Independent Director for a 5-year term starting Dec 22, 2025.
The appointee has nearly 40 years of experience and served as CFO of group company TTK Prestige for 30 years.
Shareholder approval to be sought via Postal Ballot with e-voting concluding on January 24, 2026.
Mr. Sundaresan is a Fellow Member of the ICAI with extensive expertise in corporate finance, audit, and ERP implementation.
👀 What to Watch
The appointment of a seasoned financial expert from the group's ecosystem is a positive step for corporate governance. No immediate action is required other than noting the strengthening of the board's oversight capabilities.
TTK Healthcare Appoints Former TTK Prestige CFO V Sundaresan as Independent Director
TTK Healthcare has appointed Mr. V Sundaresan as an Additional Independent Director for a five-year term effective December 22, 2025. Mr. Sundaresan is a seasoned professional with nearly 40 years of experience in finance and audit, including a 30-year tenure at TTK Prestige where he retired as CFO in 2020. The appointment is subject to shareholder approval via a postal ballot process scheduled to conclude on January 24, 2026. This appointment is expected to strengthen the company's financial governance and strategic oversight.
Key Highlights
Appointment of Mr. V Sundaresan as Additional Independent Director for a 5-year term starting Dec 22, 2025
Appointee brings 40 years of leadership experience and previously served as CFO of TTK Prestige Ltd
Shareholder approval to be sought through Postal Ballot with e-voting from Dec 26, 2025, to Jan 24, 2026
The board meeting was held on December 22, 2025, and concluded within 15 minutes
👀 What to Watch
Investors should view this as a positive governance move given the appointee's deep financial expertise and familiarity with the TTK Group. No immediate portfolio action is required.
